ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0999

CXCL13 Is a Key Driver for Migration and Differentiation of Regulatory B Cells
Abstract Number: 1000

Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Arthritis in Adulthood Among Women
Abstract Number: 1001

Risk of Malignant Melanoma and Nonmelanoma Skin Cancer in Rheumatoid Arthritis Patients Initiating Methotrexate versus Hydroxychloroquine
Abstract Number: 1002

Prostate Cancer Risk Is Not Increased in Rheumatoid Arthritis After Accounting for Retention in a Health Care System
Abstract Number: 1003

Long-term Weight Changes and Risk of Rheumatoid Arthritis Among Women in a Prospective Cohort: A Marginal Structural Model Approach
Abstract Number: 1004

The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Rheumatoid Arthritis Patients
Abstract Number: 1005

Risk of Non-vertebral Fractures Among Rheumatoid Arthritis Patients Treated with Biologic or Targeted-Synthetic DMARDs: A Multi-Database Comparative Safety Study
Abstract Number: 1006

Post-menopausal Rheumatoid Arthritis Is Inversely Associated with Lifetime High Level of Estrogen Exposure in the French E3N Cohort
Abstract Number: 1007

Atopic Dermatitis and Risk of Incident Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Abstract Number: 1008

Assessing Improved Risk Prediction of Seropositive Rheumatoid Arthritis by Environmental, Genetic, and Preclinical Plasma Metabolite Factors
Abstract Number: 1009

Missing Data and Multiple Imputation in Rheumatoid Arthritis Registries Using Sequential Random Forest Method
Abstract Number: 1010

Infection and Malignancy Outcomes in Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study
Abstract Number: 1011

Effectiveness, Safety and Quality of Life with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: First Interim Results from a German Non-Interventional, Prospective, Multi-Center Study
Abstract Number: 1012

The Global Prevalence of Rheumatoid Arthritis: A Meta-Analysis
Abstract Number: 1013

National Burden of RA in Canada 1990-2017: Findings from the Global Burden of Disease Study 2017

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].